SNSS - Earnings call transcript Q3 2019 | Viracta Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Q3 2019 Sunesis Pharmaceuticals Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]

conference being this reminder, a call recorded. is As

go turn over Chief to would Development. Officer now host conference to like Please Corporate President, Quinn, I your the Mr. Senior Vice ahead. and Financial Willie

Willie Quinn

Welcome President, everyone, us. today Officer, Judy Dayton President are Hyare, Executive Officer; and for Clinical Vice Interim Suri, Executive & Chief Commercial; With Senior Development; Chief Par me Misfeldt, Fox, thank and you Operations. joining Scientific Vice President Deepali Research Vice

provide will brief Judy details events, the corporate recent review I a will vecabrutinib the provide third and financial more program, Dayton on of quarter will XXXX. overview

We all call be the for will which we will then available. questions open for

you which future important factors we statements Company's results statements. from represents press conference the during today, Company's by filings the today's will the not with and events. are expectations qualified in SEC, on statements forth we Before remind discussed Information call, beliefs in or These actual could accurate that let those intentions, begin, forward-looking update. call concerning do that today's be today's me release as cause to set is of we materially making differ forward-looking such and intend to forward-looking

call the turn me to let that, Dayton. over With

Dayton Misfeldt

hematologic serve and to joining who as non-covalent an have exciting important as BTK covalent vecabrutinib. Thanks, treatment thank time malignancies, you inhibitors Willie. potential currently us. available new Good for for have developed believe inhibitors, afternoon for This with patients the such is resistance which to options we

it to X We vecabrutinib's move inhibitor of a patients unmet vecabrutinib, this asset, BTK look profile can new Phase to closer needs the assets. is we of lead forward testing. Our address as elaborating clinical among and how non-covalent class unique

CLL Xb/X great made or in of vecabrutinib chronic other Phase with trial progress escalation beta have phase lymphocytic we relapsed, in leukemia refractory and malignancies. of patients dose our portion the Recently

have and sixth in treated milligrams at study. this We cohort are XXX strong patients, over enrollment currently XX our in have

near-term begin dose recommended identify is populations. phase us allow to vecabrutinib goal testing defined to patient X Our the in that will

To for the groundwork prepare Phase of for this, we X have this component laid study. the

week, Phase from providing of at of we portion poster update, the clinical results ongoing the December. the presentation a will Hematology last announced detailing Xb American As trial a in and meeting be Society giving

I of will turn the in over Keep in to proprietary ASH progress further mind, [Indiscernible] time. assets, vecabrutinib. PDKX want also Judy recent the limits this that our the call we pipeline information bit a highlight to the share the with inhibitor one discuss SNS-XXX. at I made can to

we October, showing the exciting In presented models at the meeting; Conference. SNS-XXX and preclinical activity cancer tumor triple data hematologic and solid AACR-NCI-EORTC

with additional completing and activities target the to end file by for a IND pharmacology an of are manufacturing XXXX. We SNS-XXX

position. clinical the equity strong support This and from X. is investors. through start programs vecabrutinib us development we with important advance infusion $XX.X will Phase proceeds of approximately completed financing cash existing cash the a allow new institutional to an milestones our Supporting net July, In of million including with leading

our to the Paborji advance benefiting Taverna, from Dr. Medicine continues our to expertise be Technical forward Development. people and the announced & to instrumental committed PDKX Sunesis. Mehdi we both Translational Vice-President, to Nonclinical pipeline. to programs hiring look and continue We We of Pietro on and of Pietro we Mehdi’s vecabrutinib new well as experienced as Dr. as promotion the attract today as Operations Vice-President,

her to brings years experience of recently we Onetto over look benefitting addition expertise. Dr. we our to Sunesis and and development Onetto clinical Nicole Directors. in In oncology of Dr. XX hematology in forward appointed from Board to

resistance we unmet we SMS compound a advancing intolerant progressing the the X who that BTK to phase inhibitors. dose. dose rapidly is or address get is the develop vecabrutinib summary, Vecabrutinib inhibitor potential first-in-class X closer to has In PDK are of our selecting In the escalation now to XXX are covalent as to patients needs clinic.

into on details With that, Judy vecabrutinib. the will over I turn to to more call go

Judy Fox

This across To above XXX and Vecabrutinib cohorts, patients work through four year, different phase our sixth cohort adverse X identifying any as have in the currently our BID drug-related XX we we not have milligrams. higher in milligrams Dayton. higher events well grade very Thanks, and our cohorts towards dose enrolled testing been has seen we dose. are levels. tolerated date,

to to the chemokine of and with relationship see There in we higher appears promising, reduction evidence see doses. look both and increased we benefit. exposure between activity increased continue those continued Pharmacokinetics be with with pharmacodynamic clinical

promising forward to profile and covalent inhibitor with doses vecabrutinib CLL/SLL heavily cohorts without X, are mutations. look X CXXX In our XXX the phase have In re-investigated us we high-risk who encouraged will defined BTK our prognostic the so higher factors. the resistant investigators phase are and we far, with of cohort. relapse evaluate Given of generally treating patients milligram BTK pretreated poor outcome in patients to be

We will covalent to vecabrutinib also inhibitors. intolerant in to patients opportunity have our study BTK first

for seamless with in planned dose Europe. phase in expansion and ready into a identified sites are transition both the is We the X U.S. once

X the Phase t-cells Given inhibitor and as vecabrutinib in effect of profile in collaborations. of unique both patients ITK, an vecabrutinib and characterize preclinical BTK we’ll on

for neurons X to CAR-T combined of lines want data cancer and XXX from also origins. [ph] ITK BTK cell panel CLL. tissue At on genomically-profiled we presented briefly SNS-XXX. therapy meeting, has inhibitor, triple improved touch diverse the I our and note, from outcomes onco Of approved inhibition PDK

CDKNXaA number gene mutated different to We found commonly cancers. of in that CDK are sensitive a NXA mutated is deleted or The tumors particularly SNS-XXX.

in models. SNS-XXX addition AML activity anti-tumor potent shows In

continue define work. will our IND-enabling potential clinical as We further directions we

SNS-XXX by end We the file year. next IND for to an expect of

over review I will to the results. now call turn financial to Willie

Willie Quinn

Thank you, Judy.

offering beginning advance offering preferred vecabrutinib This allow important attracting successfully dose million. new the we our shares public proceeds third a us of including and gross tier of As and clinical to existed ongoing a stock investors at through of milestones in common quarter will reminder, the $XX top escalation. the completed of July, and with biopharma

$X.X for in quarterly Turning ended and the million to months loss XX, September September compared cash $XX.X months operating nine XXXX. for to for million total was as million activities results, for nine used the $XX.X quarter XXXX the ended XX, was the operations

and quarter December the million in proceeds with including increase issuing $XX.X primarily equivalents, ended in to cash $XX.X was marketable We from to XXXX. $XX.X million and million compared million our net due of cash of The as securities as cash, principle restricted $XX.X XX, by prior prepayment used loan operating with in our common Silicon X.X our million from agreement Valley loan and in Bank a on million Solar Bridge million Capital. net and preferred XX.X offset cash stock proceeds partially and $X.X Bank activities

of company ongoing is trial. vecabrutinib let's capital fund This Xb/X to open the to call the phase X With portion expected the the phase that of your Operator? initiation the questions. through

Operator

Kim first the [Operator line of Justin question from Oppenheimer. comes from Instructions] Your

is line open. Your

Justin Kim

we dosing and speak taking of said relationship congrats relationship start, at for and clinical its presentation levels? Hartaj know of the Hi at from ASH will milligram between to dose the bulk thanks questions way, range? May drug another a end Maybe concentration relationship can the escalation the just plasma carry maintain approach on high does as the me to the on linear XXX be I level and dose. the higher updates, but the the these you

Dayton Misfeldt

have address you Judy the that. question. for I’ll Thank Okay.

Judy Fox

detail and encouraged I that we're in see that say will by We with increase into what we ASH the go can more exposure is at do dose. very

Justin Kim

scheduling eligible what Can would great. the which scan the remind be by seem for of like ASH company. cut really a Okay, you us for And does will scan the a for cohorts sort of data be time and opportunity great first off? dose

Dayton Misfeldt

Yes.

include and let milligram activity address and an going have will are PK/PD I Judy through ASH would that the safety the again to information. We will XXX scan data data cohort

Judy Fox

Yes.

three The first at completion of the treatment. scan of on cycles is

Justin Kim

enrollment patient Okay. not doses maybe are enrolled pretreated Great. And to that a higher status the somewhat observed these into the company getting is study patients maybe at has fair or heavily the that just say? less of coming on

Judy Fox

patients. continue a We of to mix see

heavily are side. pretreated have the some We patients seen who less on

Justin Kim

question filing? just talk little manufacturing can And and a you XXX, Great. maybe about bit on of Okay. pharmacology activities IND last the the types a just before

Judy Fox

Okay.

might mutations meeting, did sensitivity of present pharmacology seen you XXX see that observation side, So you or enhanced deletions triple have with CDKNXA. in a on at to the intriguing as

see And moving the on so studies best to we're combination to that conducting manufacture. how exploit then just model with sensitivity, potentially in additional we in and vivo are towards GMP And mouse inhibitors. manufacturing CDKXX side,

for IND. an activities would So that do traditional you

Justin Kim

the Great. so clearing for much question. Okay. Thanks

Operator

Your next Atkins Kenneth question of line from Cowen. from the comes

open. Your line is

Kenneth Atkins

getting you're seeing that's think that per begin exceeding The order responses? get Could exposures taking thanks for ml, of the sufficient to need of guys kind to Hi BTK you efficacy? my you you think what indicates remind XXXX a ASH to you inhibition mig enough do to XXX achieve dose in us see nanograms questions. [Indiscernible]

Judy Fox

So understand in we as exposure we're and with subjects, in escalation. reminder our we relationship more dose a move threshold And dose through to continuing studying detail. patients was the healthy outcome the initial and based as are the relationship as between the understand on determined test drug you beginning disease, to

Kenneth Atkins

it. Got

at expansion and us see efficacy? does go you're de-escalate to you walk ahead seeing to cohort begin continue court open that just up given would then if that advocacy would you or process? decision an a you if and dose you through Okay where cohort, Can

Judy Fox

information be will dose number for different a to just you’ve reminder, a comes to safety and cohort, completed factors recommended as complete when prior activity escalate on of decision the given expand the or So and decision you scan. you a

look what decision dose And the made. on composite could really be at depend a data so it the will time escalation,

Kenneth Atkins

Okay. Thanks.

Operator

I Misfeldt. questions conference Instructions] back further the I you at to no to am Mr. showing now would Dayton turn time. like this [Operator

Dayton Misfeldt

Thank you.

So activity very to in signs a early of patient has good demonstrated vecabrutinib population. safety sick summarize and

our evaluate and today, dosing cohort Good for the at next all month. Thank of dose We milligram this to in patients you many you have and for Orlando afternoon. excited your participating interest support forward XXX and ASH ongoing see on to started in and call are look level. we six

Operator

for Ladies Have conference. a and day. Thank gentlemen, wonderful today's this you participation. concludes your

You may all disconnect.

Viracta Therapeutics (VIRX) 12 Nov 192019 Q3 Earnings call transcript